Objectives: The aim of this study was to determine the genetic variability of clinical isolates morphologically identified as Fusarium oxysporum and to assess if there are differences in antifungal susceptibility among the possible genetic clades obtained.
Introduction
Fusarium oxysporum is a cosmopolitan soil-borne filamentous fungus responsible mainly for superficial skin infections and onychomycosis in immunocompetent patients and disseminated infections in immunocompromised patients. Most cases of fusariosis are caused by members of the Fusarium solani species complex, followed by members of the F. oxysporum complex (FOC). 1 In a recent in vitro study, F. solani showed universal resistance to the commonly used antifungal drugs. 2 Currently, few data are available on the in vitro 3, 4 and in vivo activities of the available antifungal drugs against the members of the FOC, and as a result, the treatment of choice for fusariosis remains to be determined. This is due in part to the difficulties in the correct identification of Fusarium isolates at the species level, which means that in numerous clinical cases the aetiological agent is reported as Fusarium sp. In recent years, we have received numerous Fusarium strains of clinical and environmental origin for identification and a considerable number of them were morphologically identified as F. oxysporum. Recently, it was demonstrated that the elongation factor 1a (EF-1a) gene sequence is an excellent phylogenetic marker for identifying the Fusarium species. 5, 6 The aims of this study were: (i) to assess the degree of correlation between the morphological and molecular identification of a representative number of these isolates; (ii) to determine their genetic variability and whether they are included in any of the molecular clades of the FOC described previously; and (iii) to assess whether there are significant differences in antifungal susceptibility among the possible genetic clades obtained.
Materials and methods
A total of 28 F. oxysporum isolates were included in the study. Twenty-three of these isolates, which were mainly from clinical sources, were sent to our laboratory from different clinical centres for species identification. Those isolates were identified following the conventional morphological criteria and deposited in the fungal collection at the Faculty of Medicine in Reus (FMR), Spain. In addition, five reference isolates, which represent different F. oxysporum clades described by O'Donnell et al., 5 were used for comparison. These latter isolates were obtained from the Agricultural Research Service (ARS/NRRL), USA.
To confirm morphological identification and to determine genetic variability, we sequenced a region of the EF-1a gene of the 28 isolates mentioned earlier. We followed the procedures for DNA extraction, amplification and sequencing of the analysed region previously described by Gilgado et al. 7 with some modifications. We used the primers EF-1H and EF-2T 6 with an annealing temperature of 558C and the PCR product was purified using the Illustra GFX TM PCR DNA and Gel Band Purification Kit (General Electric Healthcare, Buckinghamshire, UK). For the phylogenetic analysis, apart from those 28 sequences, we included 22 sequences of this region retrieved from the GenBank and belonging to the four main clades of the FOC described by O'Donnell et al. 5 The sequences were aligned using the Clustal X (version 1.8) computer program followed by manual adjustments with a text editor. The phylogenetic analysis was performed using PAUP* version 4.0b10. Maximum parsimony trees (MPT) were obtained after one hundred heuristic searches with random sequence addition and tree bisection-reconnection branch-swapping algorithms, collapsing zero-length branches and saving all minimal-length trees (MulTrees).
The in vitro activity of 11 antifungal drugs against the 28 isolates was determined using a microdilution reference method 8 with some modifications. The isolates were grown on potato dextrose agar (PDA; Difco Laboratories, Detroit, MI, USA) plates and incubated at 258C for 7 days. The inocula were adjusted to a final concentration of 4Â10 3 -5Â10 4 conidia/mL with a haemocytometer and verified by quantitative colony counts on PDA plates. The antifungal agents tested were amphotericin B, albaconazole, fluconazole, itraconazole, ketoconazole, posaconazole, ravuconazole, voriconazole, flucytosine, micafungin and terbinafine. Fluconazole, flucytosine and micafungin were diluted in sterile distilled water and the rest were diluted in DMSO. Final drug concentrations ranged from 64 to 0.12 mg/L for fluconazole and flucytosine, from 128 to 0.25 mg/L for micafungin and from 16 to 0.03 mg/L for the rest. The MIC endpoint for amphotericin B, terbinafine and most triazoles was defined as the lowest concentration that produced complete inhibition of growth (MIC 0); for ketoconazole, fluconazole, flucytosine and micafungin, the endpoint was defined as the lowest concentration that produced 50% inhibition of growth (MIC 2). Paecilomyces variotii ATCC 36257 was included as a quality control strain. Testing was performed twice on two different days and in those instances where the results did not coincide it was repeated a third time. For those strains, the MIC was considered to be the mode of the three MIC values. To compare the antifungal susceptibility values of the different molecular clades, we used the Mann-Whitney U-test (P,0.05), implemented in GraphPad version 4.0 for Windows. 
Results and discussion
With the primers used, we were able to amplify and sequence a fragment of 531 bp of the EF-1a gene. All 23 isolates received for identification were morphologically identified as F. oxysporum and confirmed at the molecular level by comparison with the reference strains (100% of correlation). Parsimony analysis of the dataset yielded 36 phylogenetic trees of 55 steps (Figure 1) . We obtained four main molecular clades (1, 2, 3 and 4) that were previously described by O'Donnell et al. 5 Clade 3 was the biggest and the most variable, grouping four different subclades (3a, 3b, 3c and 3d). We did not find any relationship between the biogeographical origin of the isolates and the molecular groups. Phylogenetic clades different from those previously described in the O'Donnell et al.
5 study were not found. Results of the susceptibility tests are shown in Table 1 . In general, all the drugs showed poor activity. Amphotericin B showed the lowest total geometric mean (GM) MIC (2.32 mg/L) with no statistically significant differences among the different clades (P. 0.05). The in vitro activity of amphotericin B against F. oxysporum reported in the literature is very variable, with MICs ranging from 0.5 to .16 mg/L. 3, 4 Clinical experience confirms the poor efficacy of amphotericin B in treating infections by F. oxysporum. 9 Terbinafine showed the second-lowest GM MIC
3 who obtained a GM MIC of 10.77 mg/L after testing 14 clinical isolates of F. oxysporum, mainly from deep infections. This disagreement could be due to the fact that the majority of our isolates came from superficial infections, although the two strains from samples of deep infections included in our study also showed very low MICs (0.5 mg/L, in both cases). According to our results, terbinafine showed very variable MIC values, ranging from 0.125 to 32 mg/L and statistically significant differences among the different clades. The only strain belonging to clade 4 was resistant (GM MIC 32 mg/L) whereas all the strains of clades 1 (GM MIC 0.25 mg/L) and 2 (GM MIC 0.35 mg/L) showed considerably lower values. Nevertheless, within clade 3 antifungal susceptibility depended on the subclade. All the strains of subclade 3a showed low MICs (GM MIC 0.46 mg/L), whereas those of subclades 3c and 3d were resistant (GM MIC 32 mg/L) and those of subclade 3b were strain-dependent.
The other drugs tested were practically inactive, including voriconazole, which showed a GM MIC value of 6.09 mg/L, agreeing with previous in vitro studies. 3, 4 Contrary to these results, Gorman et al.
10 reported a case of F. oxysporum pneumonia where an immunocompetent host did in fact respond to oral voriconazole therapy. Ravuconazole, ketoconazole, albaconazole and posaconazole were the next most active drugs in decreasing order of potency. Fluconazole, itraconazole, flucytosine and micafungin were not active against any of the isolates (data not shown).
In conclusion, F. oxysporum showed a response to antifungals similar to that of F. solani, 2 displaying high resistance to all the drugs tested, with the exception of terbinafine. Moreover, the present work confirms the molecular variability within the FOC, as previously demonstrated by other studies 5 and showed that this variability is reflected in the susceptibility to terbinafine of isolates from this complex.
